Chengdu Kanghong Pharmaceutical Group (688739.SH): High-dose Influenza Virus Split Vaccine Enters Phase I Clinical Trial.

Wisdom Finance and Economics APP News, Chengda Biotechnology (688739.SH) announced that recently, its wholly-owned subsidiary Chengda Biotechnology (Benxi) Co., Ltd. (referred to as "Benxi Subsidiary") has developed a high-dose influenza virus split vaccine, which has been approved by the National Medical Products Administration for clinical trials and has completed all preparations for Phase I clinical trials, officially entering the Phase I clinical trial stage.